Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

Pfizer plans to invest $1 billion in China by 2030 to support innovation, diagnostics, and the biotech sector, aligning with ...

Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new ...

Viracta Therapeutics has announced a restructuring to focus on its lead oncology candidate, nana-val, targeting EBV-positive ...

Japanese ophthalmology company Santen Pharmaceutical has crossed the East China Sea in its latest collaboration, announced on ...

AlloVir will merge with Kalaris Therapeutics in an all-stock transaction, with Kalaris shareholders holding a 75% stake in ...

GEN1047, GEN3017, and GEN1056—to refocus resources, following its recent $1.8 billion acquisition of ProfoundBio. The move ...

US generic drugmaker Viatris (Nasdaq: VTRS) announced robust financial results for the third quarter of 2024, driven by ...

According to UNICEF's State of the World's Children 2023 report, in Latin America and the Caribbean, 6.8 million children did ...

Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong ...

French biotech Transgene today revealed it has entered into a license agreement with Germany-based contract development and ...

Following the news that Donald Trump is the winner of the 2024 US Presidential Election, Morningstar Equity analyst Julie ...